Challenges in translating vascular tissue engineering to the pediatric clinic

Vascular Cell

Table 1 Late term status after TEVG implantation in clinical trial

Patient	Age at Operation (Years)	Patient Status	Graft Status	Graft Patency	Graft Related Complications
1	2	alive	intact	patent	none
2	1	alive	intact	patent	none
3	7	alive	intact	patent	stenosis
4	21	alive	intact	patent	none
5	4	alive	intact	patent	none
6	12	alive	intact	patent	none
7	17	alive	intact	patent	none
8	19	dead	intact	patent	none
9	3	alive	intact	patent	stenosis
10	2	dead	intact	patent	none
11	13	alive	intact	patent	stenosis
12	2	dead	intact	patent	none
13	2	alive	intact	patent	thrombosis
14	2	alive	intact	patent	none
15	2	alive	intact	patent	none
16	2	alive	intact	patent	none
17	24	alive	intact	patent	none
18	1	alive	intact	patent	stenosis
19	11	alive	intact	patent	none
20	2	alive	intact	patent	none
21	3	alive	intact	patent	none
22	4	alive	intact	patent	none
23	4	alive	intact	patent	none
24	13	alive	intact	patent	none
25	2	dead	intact	patent	none

Most recent follow-up at mean of 5.8 years showed no graft-related mortality and no evidence of aneurysm formation, graft rupture, or ectopic calcification. 4 out of 25 patents developed asymptomatic stenosis that was picked up on routine serial imaging and were successfully treated with angioplasty. All implanted TEVG are currently intact and patent. (Adapted from Hibino (2010) with permission from Elsevier [40]).

ISSN: 2045-824X